
    
      This is a multi-center, double-blind, placebo-controlled, randomized, Phase 2a study of
      ION-827359 in up to 180 participants. The participants will be randomized to receive oral
      inhalation of either ION-827359 or placebo for up to 13 weeks. At the end of 13 weeks,
      participants will enter a 10-week post-treatment evaluation period.
    
  